Compare PARR & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PARR | ANIP |
|---|---|---|
| Founded | 1984 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2000 | 1999 |
| Metric | PARR | ANIP |
|---|---|---|
| Price | $65.53 | $72.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $57.00 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 1.5M | 326.6K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1313.56 | 419.23 |
| EPS | ★ 7.16 | 3.32 |
| Revenue | ★ $2,443,066,000.00 | $206,547,000.00 |
| Revenue This Year | N/A | $23.05 |
| Revenue Next Year | $4.73 | $14.08 |
| P/E Ratio | ★ $8.80 | $22.30 |
| Revenue Growth | ★ 30.99 | 2.47 |
| 52 Week Low | $12.04 | $56.71 |
| 52 Week High | $63.68 | $99.50 |
| Indicator | PARR | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 75.63 | 41.52 |
| Support Level | $34.55 | $71.29 |
| Resistance Level | N/A | $84.47 |
| Average True Range (ATR) | 3.16 | 2.30 |
| MACD | 0.89 | 0.15 |
| Stochastic Oscillator | 93.60 | 34.97 |
Par Pacific Holdings Inc is an oil and gas company that manages and maintains interests in energy and infrastructure businesses. The company has three reportable segments namely Refining, Under its refining business, the company produces ultra-low-sulfur diesel, gasoline, jet fuel, marine fuel, LSFO, and other associated refined products. Its Retail includes operation licenses out brands to serve the retail consumer. Through the Logistics segment, crude shipments are delivered to the refineries, in addition to finished products that are exported. It generates maximum revenue from the Refining segment.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.